Difference between revisions of "Dosulepine-bupropion"

From Psychiatrienet
Jump to: navigation, search
Line 8: Line 8:
 
| start =  
 
| start =  
 
* '''Day 1:''' simultaneously start administration of bupropion in a dosage of 150 mg/day and continue administration of dosulepine according to the scheme above.
 
* '''Day 1:''' simultaneously start administration of bupropion in a dosage of 150 mg/day and continue administration of dosulepine according to the scheme above.
* '''Day 8:''' stop administration of dosulepine and continue administration of bupropion only in a dosage of 300 mg/day.
+
* '''Day 8:''' stop administration of dosulepine and continue administration of bupropion.
 
| info =  
 
| info =  
 
* Bupropion is a strong inhibitor of CYP2D6, which metabolises dosulepine. }}
 
* Bupropion is a strong inhibitor of CYP2D6, which metabolises dosulepine. }}

Revision as of 08:09, 23 July 2009

dosulepin
Type antidepressant
Group TCA
links
ATC-code N06AA16
PubChem 13473
PubMed dosulepin
Kompas (Dutch) dosulepin
Wikipedia dosulepin
Bupropion
Type Antidepressant
Group other
links
ATC-code N06AX12
Medscape Bupropion
PubChem 444
PubMed Bupropion
Kompas (Dutch) Bupropion
Wikipedia Bupropion

Switch medication from dosulepine to bupropion.[1] [2]

Nietinrijdenbord.png Stop dosulepine
  • Before day 0: gradually reduce dosage of dosulepine to a maximum of 100 mg/ day, when this dosage is > 100 mg/day.
  • Day 1-3: reduce dosage of dosulepine to 50 mg/day.
  • Day 4-7: reduce dosage of dosulepine to 25 mg/day.
Eenrichtingbord.png Start bupropion
  • Day 1: simultaneously start administration of bupropion in a dosage of 150 mg/day and continue administration of dosulepine according to the scheme above.
  • Day 8: stop administration of dosulepine and continue administration of bupropion.
Infobord.png More information
  • Bupropion is a strong inhibitor of CYP2D6, which metabolises dosulepine.
  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.